Mohr Davidow Ventures related stories
All articles and analysis
Infusionsoft Buys GroSocialInfusionsoft, a maker of sales and marketing software for small businesses, has acquired social media marketing software company GroSocial. Terms of the deal were not released. Infusionsoft recently sealed $54 million in growth capital financing led by Goldman Sachs.
- Goldman Pours $54M into Infusionsoft
Goldman Sachs made a $54 million growth capital investment in Infusionsoft, maker of sales and marketing software for small businesses. The money will be used for product development and marketing and sales, among other growth efforts. The latest round includes participation from Arthur Ventures. Infusionsoft has received a total of $71 million to date, and is also backed by Mohr Davidow Ventures and Signal Peak Ventures.
- Hudson Clean Energy in $305m solar exit
The New Jersey-based firm has sold Recurrent Energy, one of seven clean energy investments Hudson has made since its founding in 2007.
- Gene-mapper raises $100m from venture heavyweights
Pacific Biosciences has lured the backing of an eclectic consortium of investors including Kleiner Perkins, Ontario Teachers’ and fixed income hedge fund Deerfield.
- Social networking continues to lure venture capital
LinkedIn, SodaHead, Twitter and I’m In Like With You are among the most recent companies to receive backing in the increasingly crowded social networking sector.
- Sevin Rosen to extend Funds VII and VIII, waive management fees
The US venture firm has asked LPs to extend partnership terms, citing an abysmal IPO environment and slowdowns in M&A and the broader economy. Those factors are ‘red flags’ for the VC market, but a fund extension is business as usual, according to the NVCA’s president.
- Crescendo Bioscience Closes on $28M
Crescendo Bioscience, a molecular diagnostics company, has raised $28 Million in a Series D round led by Skyline Ventures and Safeguard Scientifics Inc. Existing investors Mohr Davidow Ventures, Kleiner Perkins Caufield & Byers, and aeris CAPITAL also participated. Crescendo Bioscience is focused on developing and commercializing quantitative blood tests for rheumatoid arthritis and other auto-immune diseases.
- Mohr Davidow continues cutback trend
The US-based firm has become the third venture capital firm to make a second cutback on earlier fundraising, cutting a further $200m from its seventh fund.
- Whilst VCs struggle, buyout funds rebound
As many VC firms search for investments whilst nursing their portfolios back to health, buyout firms are finding the current environment much more to their liking.